Zynex — Investor Presentation (December 2013)
26 slides from Zynex's investor presentation, Dec 31, 2013
Slide 1: Zynex
ZYNIEXD
Slide 2: Forward Looking Statements
Forward Looking Statements Statements made in this presentation include financial estimates and forward-looking statements that are not historical facts. Each of these estimates and forward-looking statements involves risk and uncertainties. These estimates are based on present circumstances, inform
Slide 3: Zynex Overview
Zynex Overview Medical Device Manufacturer & Compound Pharmacy Non-invasive, conservative pain treatment EEG & Sleep diagnostics Blood volume monitoring Physician and hospital billing International sales Publicly Traded OTCQB: ZYXI In operation since 1996, headquartered in Lone Tree, Colorado >40%+
Slide 4: Business Structure
Business Structure Business Structure 12/19/2013 4 OTCQB: ZYXI
Slide 5: Business Unit Summary
Business Unit Summary ZYNEX MEDICAL (ZMI) Non-invasive electrotherapy pain management devices "TENS" (98% of historical revenue) RX required, insurance billed >70% GP, >40% recurring revenue (consumable supplies) Topical/transdermal pain cream (introduced Dec 2013) RX required, insurance billed, com
Slide 6: Products - Zynex Medical
Products - Zynex Medical Complete line of electrotherapy pain management devices-FDA cleared and CE marked Augments healing, alleviates swelling through increased blood circulation, and reduces both acute/chronic pain through the use of electrical currents Consumables required Require a prescription
Slide 7: Products - Zynex Medical (Stroke/spinal cord rehabilitation)
Products - Zynex Medical Stroke/spinal cord rehabilitation devices-FDA cleared and CE marked Augment healing, as well as assist in recovery for stroke, Spinal Cord Injuries and Traumatic Brain Injury, retrains muscles, increases range of motion Consumables required 12/19/2013 7 NeuroMove Consumables
Slide 8: Products - Zynex Neurodiagnostics
Products - Zynex Neurodiagnostics EEG/Sleep diagnostic devices used in Neuro clinics, sleep diagnosis labs and for home sleep diagnosis B:B sale Not dependent on insurance reimbursement 12/19/2013 8 BWIII - (in lab) Sleep Diagnostic product Sleep Profiler- (home) Sleep Diagnostic product OTCQB: ZYXI
Slide 9: Products - Monitoring Solutions
Products - Monitoring Solutions In development - non invasive blood volume monitor Used in operating and recovery rooms to detect blood loss and internal bleeding Clinical trials commenced Patent filed 12/19/2013 9 Blood Volume Monitor (in development) OTCQB: ZYXI
Slide 10: Revenue Growth
Revenue Growth 12/19/2013 10 OTCQB: ZYXI
Slide 11: Financial Summary
Financial Summary 12/19/2013 11 OTCQB: ZYXI
Slide 12: Balance Sheet
Balance Sheet Balance Sheet 12/19/2013 12 OTCQB: ZYXI
Slide 13: Available Market
Available Market 12/19/2013 13 OTCQB: ZYXI PAST AVAILABLE MARKET ~$4B PAST AVAILABLE MARKET ~$4B CURRENT AVAILABLE MARKET ~$7B CURRENT AVAILABLE MARKET ~$7B ZYNEX MEDICAL ZYNEX MEDICAL Electrotherapy Devices $550M Electrotherapy Devices $275M Compound Pain Cream $1.8B ZYNEX MONITORING SOLUTIONS ZYNE
Slide 14: What Happened to Business
What Happened to Business Electrotherapy Industry (Zynex Medical - TENS) Healthcare Reform CMS Decision TENS devices Lower Back Pain indication no longer covered by Medicare Affordable Care Act Commercial insurance following CMS Physicians confused by general "reform" change and required to generate
Slide 15: Zynex Path to Recovery
Zynex Path to Recovery Zynex Improve current TENS business as quickly as possible Expense reductions to current demand (headcount/other ancillary) Renegotiated current building lease Focus on workers compensation electrotherapy (TENS) orders (highest collection rate) Diversification Pain Cream Creat
Slide 16: Zynex Path to Recovery (Monitoring and Billing)
Zynex Path to Recovery Zynex Monitoring Solutions Untapped market need blood volume monitoring (safer surgery/recovery) Non-invasive B:B Product development Zynex Billing and Consulting Service based revenue Leverage insurance billing core competency 12/19/2013 16 OTCQB: ZYXI
Slide 17: Zynex - Looking Forward
Zynex - Looking Forward Zynex Medical (ZMI) Pain Cream/Compound Pharmacy facts Complements Zynex TENS non-invasive pain management product and is sold through same TENS channel and customer Highly fragmented with low concentration Approximately 80%+ GM Zynex NeuroDiagnostics(ZND) EEG/Sleep Diagnosti
Slide 18: Zynex - Looking Forward (Monitoring and Billing)
Zynex - Looking Forward Zynex Monitoring Solutions: Blood Volume Monitor at commercialization Early warning that patient condition is likely to deteriorate Utilizes multiple physiological Enables a higher level of care than traditional vital sign monitoring Effective in multiple care environments (e
Slide 19: Future Objectives
Future Objectives Listing on AMEX/NASDAQ Develop devices and applications with high GPM Continue to grow recurring revenue Take only calculated risks Continue net earnings growth plan Positive free cash flow Utilize a mix of acquisitions and organic based growth to drive valuation=stock price=privat
Slide 20: History
History History 12/19/2013 20 OTCQB: ZYXI
Slide 21: Corporate & Ownership Structure
Corporate & Ownership Structure 12/19/2013 21 Common Stock: 31,000,000 shares outstanding OTCBB: ZYXI Auditors: GHP Horwath Counsel: Perkins Coie OTCQB: ZYXI
Slide 22: Management Team Bio
Management Team Bio Thomas Sandgaard has been the Chairman of the Board, President and Chief Executive Officer of Zynex, Inc. since founding the company in 1996. He has previously held management positions with companies such as ITT, Siemens, GN Danavox, Dataco and Philips. Most of his work has been
Slide 23: Management Team Bio
Management Team Bio Robert "Bob" Cozart is the VP of Technical Operations who develops and manages all of the teams that make up the Purchasing, Production, Service, Warehouse, Facilities, and Shipping and Receiving departments. Mr. Cozart has over 26 years of management experience in electronics ma
Slide 24: Summary
Summary Summary 12/19/2013 24 High GPM of >70% >40%+ recurring revenue >40,000 units in the field >200,000 patients helped since inception Estimated $7b market OTCQB: ZYXI
Slide 25: Contact Information
Contact Information For more information, please contact: Investor Relations Zynex, Inc. 9990 Park Meadows Drive Lone Tree, CO 80124 Telephone: (303) 703-4906 Facsimile: (303) 347-9153 www.zynex.com 12/19/2013 25 OTCQB: ZYXI
Slide 26: Stock Symbol ZYXI
Stock Symbol ZYXI 12/19/2013 26 OTCQB: ZYXI